Wang Yan v. Rewalk Robotics Ltd.’s Empirical Analysis
2018
Citation profile
1 district ·
Relationships
Applies 15 U.S.C. § 77K (§ 11 of the Securities Act of 1933) · 15 U.S.C. § 77O (§ 15 of the Securities Act of 1933) · 15 U.S.C. § 78A (§ 1 of the Securities Exchange Act of 1934) · 15 U.S.C. § 78U (§ 21e of the Securities Exchange Act of 1934) · 21 U.S.C. § 360L (Federal Food, Drug, and Cosmetic Act)
Relies on Bell Atlantic Corp. v. Twombly · Ashcroft v. Iqbal · Lujan v. Defenders of Wildlife · Bennett v. Spear · Watterson v. Page
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 2 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“continue to engage and fund researchers and organizations to conduct clinical studies to demonstrate the functionality and utilization of ReWalk and to highlight economic benefits of reductions in medical complications associated with spinal cord injury.”
1 later decision quote this exact passage“the FDA specifically determined, in June 2014, that the . . . device's failure to prevent a fall would be reasonably likely to cause serious injury or death to the user and place individuals assisting the user at the risk of harm from a potential fall.”
1 later decision quote this exact passage“the registrant knew, as of the time of the offering, that (1) a risk factor existed; (2) the risk factor could adversely affect the registrant's present or future business expectations; and (3) the offering documents failed to disclose the risk factor.”
1 later decision quote this exact passage
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.